Integrated biopharmaceutical company ThromboGenics has obtained Health Canada approval for Jetrea (ocriplasmin) for the treatment of symptomatic vitreomacular adhesion (VMA). Launch of the drug in Canada will be conducted by Alcon, ...
Integrated biopharmaceutical company ThromboGenics has announced the launch of Jetrea in Denmark and Sweden by Alcon, a division of Novartis. Alcon expects to roll out the European Commission approved Jetrea, which is indicated for the ...
Rockwell Medical, a fully-integrated biopharmaceutical company, has received a new patent for Soluble Ferric Pyrophosphate (SFP) formulation for iron-delivery in hemodialysis patients from the Canadian Intellectual Property Office. ...